AstraZeneca plc CEO Net Worth

Last Updated Mar 10, 2025
CEO NamePascal Soriot
NationalityFrance
Net Worth Estimation$40 million

Pascal Soriot's estimated net worth of $40 million primarily stems from his long tenure as CEO of AstraZeneca plc, earning substantial annual compensation packages, stock awards, and performance bonuses. Additional wealth is attributed to accrued share options, investments, and prior executive roles at global pharmaceutical companies.

Pascal Soriot's estimated net worth of $40 million is 40% of the maximum and 400% of the minimum CEO net worth in the healthcare business category. His net worth positions him in the mid-upper range among peers with estimated values between $10 million and $90 million.

Business Category: Healthcare

Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 90000000 USD


Pascal Soriot Performance in AstraZeneca plc

Pascal Soriot, CEO of AstraZeneca plc, demonstrates strategic leadership by driving innovation and global expansion, particularly in oncology and COVID-19 vaccine development. His decisive actions in portfolio prioritization and R&D investment have significantly improved company performance and market valuation. Under Soriot, AstraZeneca achieved robust revenue growth and strengthened its position as a leading biopharmaceutical firm.


Latest News

AstraZeneca CEO Pascal Soriot clinched a drug price deal with President Trump, agreeing to lower prescription costs for Medicaid, which Trump described as cutting prices to "the lowest price anywhere in the world." Soriot's reaction at the press conference went viral for its unusual expression, and he also discussed AstraZeneca's plans for US growth and direct medicine sales to patients.

http://www.hindustantimes.com/world-news/pascal-soriot-astrazeneca-ceos-bizarre-expression-at-trumps-presser-viral-trying-to-control-watch-101760138710537.html
Source:



Disclaimer.
The information provided in this document is for general informational purposes only and is not guaranteed to be complete. While we strive to ensure the accuracy of the content, we cannot guarantee that the details mentioned are up-to-date or applicable to all scenarios. Topics about AstraZeneca plc are subject to change from time to time.

Comments

No comment yet